Pancreatic cancer gene study targets muscle wasting

NCT ID NCT05275075

Terminated Knowledge-focused Sponsor: University of Oklahoma Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study aimed to find genetic differences, called microRNAs, that might explain why some pancreatic cancer patients lose muscle mass (cachexia). Researchers planned to analyze tumor samples from 40 patients undergoing surgery, focusing on African Americans who may be at higher risk. The study was terminated early, so findings are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could help identify genetic markers for cachexia, leading to earlier detection and better management of muscle wasting in pancreatic cancer patients.
What could go wrong: This was a small pilot study that ended early, so results may be limited. It only looked at tumor samples, not treatments, so it won't directly improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RESECTABLE PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Cachexia pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RESECTABLE PANCREATIC ADENOCARCINOMA

Contacts and locations

Locations

Stephenson Cancer Center

Oklahoma City, Oklahoma, 73117, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.